Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Ou, Sai-Hong Ignatius; Kwak, Eunice L.; Siwak-Tapp, Christina; Dy, Joni; Bergethon, Kristin; Clark, Jeffrey W.; Camidge, D. Ross; Solomon, Benjamin J.; Maki, Robert G.; Bang, Yung-Jue; Kim, Dong-Wan; Christensen, James; Tan, Weiwei; Wilner, Keith D.; Salgia, Ravi; Iafrate, A. John

doi:10.1097/JTO.0b013e31821528d3

서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

S-Space

Publications

Detailed Information

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Cited 353 time in Web of Science Cited 392 time in Scopus

Export

Authors: Ou, Sai-Hong Ignatius; Kwak, Eunice L.; Siwak-Tapp, Christina; Dy, Joni; Bergethon, Kristin; Clark, Jeffrey W.; Camidge, D. Ross; Solomon, Benjamin J.; Maki, Robert G.; Bang, Yung-Jue; Kim, Dong-Wan; Christensen, James; Tan, Weiwei; Wilner, Keith D.; Salgia, Ravi; Iafrate, A. John

Issue Date: 2011-05

Publisher: Elsevier Inc.

Citation: Journal of Thoracic Oncology, Vol.6 No.5, pp.942-946

Abstract: Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.